Therefore, we believe that the independent prognostic factors found in our study, combined with the identification of classic biomarkers associated with frailty, such as age ≥ 80 years, malnutrition (albumin < 3.5 g/dL or geriatric BMI < 22), and KPS < 70, may be valuable tools for selecting older adults with DLBCL for new therapies capable of offering promising outcomes, such as those listed above, as well as for attenuated immunochemotherapeutic regimens, such as R-MiniCHOP, R-MiniCHOP of the elderly, and protocols not based on anthracyclines. This evidence concerns the gene ALB and diffuse large B-cell lymphoma.